13th International Conference on Myasthenia Gravis and Related Disorders

第13届重症肌无力及相关疾病国际会议 项目摘要/摘要 重症肌无力(MG)的治疗--一种导致严重肌肉的罕见获得性自身免疫综合征 虚弱、严重残疾和预期寿命下降--在过去的几年里有了显著的改善 几十年。然而，许多知识差距仍然存在，以改善MG患者的预后，包括 了解MG的起源，确定导致慢性病的因素，并找到 治愈这种疾病的方法。为了解决这些未得到满足的需求，纽约科学院和 美国重症肌无力基金会将召开为期3天的第13届重症肌无力国际会议 2017年5月15日至17日，纽约，重症肌无力及相关疾病。这次会议将 召集了大约300名与会者--包括学术界的基础科学家和临床研究人员， 行业和政府；医生；制药战略家；以及患者权益倡导者-努力 消除上述知识差距。会议将结合基础、翻译和 临床研究人员，并将以一种独特的形式，以关键的开放研究为中心的简短、集中的演讲为特色 问题，13次全体会议的重点是：神经肌肉接头的结构和功能， 先天性综合征、血清学表型、自身免疫机制、近期临床 发展，神经肌肉疾病的动物模型，MG治疗的最新进展，以及全球MG 治疗指南。该计划的五个主要目标是：(I)为基础、翻译、 和来自学术界和工业界的临床研究人员在 MG研究；(2)探索和鼓励多学科和多部门合作，以加强 重症肌无力及其相关自身免疫性和神经肌肉疾病的研究方法；(Iii)综述目前的重症肌无力 治疗方案、正在进行的临床试验以及临床面临的挑战和限制；(Iv)确定 进一步突破所需的知识差距和未来研究方向；以及(V)展示和 鼓励职业生涯早期、女性和代表性不足的少数族裔调查人员通过短期调查参与 演讲、海报展示、旅行奖学金、职业指导活动和打折注册。这个 会议目标与国家神经疾病和中风研究所(NINDS)的使命非常一致 支持神经疾病方面的新知识的发展。此外，NINDS的具体目标 将满足传播关于科学发现及其对神经健康的影响的信息 通过同时直播会议和发布会议后发布的持久、开放的、 纽约科学院年鉴中符合第508条的会议报告，该报告将分发 在会议上向全球研究和医学界交流科学知识和思想。 只有通过这次会议设想的跨领域协作研究，我们才能充分指导 该领域的研究进展，特别是关于潜在的创新治疗方法。

13th International Conference on Myasthenia Gravis and Related Disorders PROJECT SUMMARY / ABSTRACT The treatment for myasthenia gravis (MG) — a rare, acquired autoimmune syndrome resulting in severe muscle weakness, significant disability, and decreased life expectancy — has improved dramatically in the last several decades. However, many knowledge gaps still remain to improving MG patient outcomes including the understanding the origin of MG, identifying the factors that contribute to chronic disease, and finding a way to cure the disease. To address these unmet needs, the New York Academy of Sciences and the Myasthenia Gravis Foundation of America will convene the 3-day 13th International Conference on Myasthenia Gravis and Related Disorders on May 15 – 17, 2017, in New York City, NY. This conference will convene approximately 300 attendees — including basic scientists and clinical investigators in academia, industry, and government; physicians; pharmaceutical strategists; and patient advocates — in an effort to address these aforementioned knowledge gaps. Conference sessions will combine basic, translational, and clinical researchers and will feature a unique format of short, focused talks centered on critical open research questions, with the 13 plenary sessions focusing on: structure and function of the neuromuscular junction, congenital syndromes, serological phenotypes, mechanisms of autoimmunity, recent clinical developments, animal models of neuromuscular disease, MG treatment updates, and global MG treatment guidelines. The five central aims of this program are to: (i) provide a forum for basic, translational, and clinical researchers from academia and industry to present and discuss the most up-to-date findings in MG research; (ii) explore and encourage multidisciplinary and multi-sector collaborations to enhance investigative approaches into MG and related autoimmune and neuromuscular disorders; (iii) review current MG therapeutic options, ongoing clinical trials, and challenges and limitations faced in the clinic; (iv) identify knowledge gaps and future directions of research required for further breakthroughs; and (v) showcase and encourage the participation of early career, female, and underrepresented minority investigators via short talks, poster presentations, travel fellowships, career mentoring activities, and discounted registration. The conference goals align well with the mission of the National Institute of Neurological Disorders and Stroke (NINDS) to support the advancement of new knowledge on neurological disorders. In addition, the NINDS’ specific goal of disseminating information about scientific discoveries and their implications for neurological health will be met via a live simulcast broadcast of the meeting and the publication of a post-conference, enduring, open-access, Section 508-compliant Meeting Report in Annals of the New York Academy of Sciences, which will distribute the scientific knowledge and ideas exchanged at the meeting to the global research and medical communities. Only through cross-field collaborative research envisioned as a result of this conference can we fully guide research forward in the field, particularly with respect to potential innovative therapeutic approaches.